Overview

Gender

male

Investor Type

Investment Partner,Angel

Steven Paul is our Interim President of R&D, a member of the Board of Directors and a Venture Partner at Third Rock Ventures. Steven Paul has had a distinguished career in neuroscience with an extensive track record in CNS drug discovery and development. He joined Third Rock in 2010, where he serves as a senior advisor to the firm and participates in the ideation and development of new companies.

Steven Paul also currently leads the Appel Alzheimer's Disease Research Institute at Weill Cornell Medical College. Preceding his appointment at Weill Cornell, Steven Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including President of the Lilly Research Laboratories, and Vice President of Discovery Research and Neuroscience Research. As President of the Lilly Research Laboratories, he was responsible for the company's overall R&D strategy, expanding its efforts in oncology and biotechnology and resulting in a pipeline of approximately 70 new molecular entities.

Prior to Lilly, Steven Paul served as Scientific Director of the National Institute of Mental Health. He has also served as Medical Director in the Commissioned Corps of the United States Public Health Service. Steven Paul has authored or co-authored more than 500 papers and book chapters.

He is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences.

He currently serves on the board or as a trustee of several organizations, including Sage Therapeutics, Alnylam Pharmaceuticals, the Sigma Aldrich Company and the Foundation for the NIH.

Steven Paul holds a B.A. in biology and psychology from Tulane University and an M.S. and M.D. from the Tulane University School of Medicine.